_id
69171acd3c536f8df23165c9
Ticker
SXTP
Name
60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange
NASDAQ
Address
1025 Connecticut Avenue NW, Washington, DC, United States, 20036
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.60degreespharma.com
Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Last Close
0.5
Volume
301920
Current Price
0.61
Change
0.0231
Last Updated
2026-01-07T12:43:50.969Z
Image
data:image/webp;base64,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
Ipo Date
2023-07-12T00:00:00.000Z
Market Cap
2179103
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.349
Sentiment Sources
1
Rating
5
Target Price
4.4
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
437602
Cost Of Revenue
537690
Gross Profit
-100088
Operating Expenses
2225437
Operating Income
-2325525
Interest Expense
1708
Pretax Income
-2316786
Net Income
-2317036
Eps
-0.6304161688759912
Dividends Per Share
-
Shares Outstanding
4230448
Income Tax Expense
250
EBITDA
-2292248
Operating Margin
-531.424673561821
Total Other Income Expense Net
8739
Cash
4115779
Short Term Investments
0
Receivables
674036
Inventories
527004
Total Current Assets
6309209
Property Plant Equipment
227752
Total Assets
6689344
Payables
1391347
Short Term Debt
8772
Long Term Debt
144992
Total Liabilities
2342386
Equity
4430220
Bs_currency_symbol
USD
Depreciation
22830
Change In Working Capital
-159651
Cash From Operations
-2109072
Capital Expenditures
9998
Cash From Investing
-25487
Cash From Financing
4282178
Net Change In Cash
2148849
Cf_currency_symbol
USD
PE
-
PB
0.506069285498237
ROE
-52.300698385181775
ROA
-34.63771634408396
FCF
-2119070
Fcf Percent
-4.842459586564961
Piotroski FScore
1
Health Score
30
Deep Value Investing Score
6
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
4
Growth Investing Score
3
Momentum Investing Score
3.5
Net Net Investing Score
5.5
Quality Investing Score
2
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
437602
Quarters > 0 > income Statement > cost Of Revenue
537690
Quarters > 0 > income Statement > gross Profit
-100088
Quarters > 0 > income Statement > operating Expenses
2225437
Quarters > 0 > income Statement > operating Income
-2325525
Quarters > 0 > income Statement > interest Expense
1708
Quarters > 0 > income Statement > pretax Income
-2316786
Quarters > 0 > income Statement > net Income
-2317036
Quarters > 0 > income Statement > eps
-0.6304161688759912
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
3675407
Quarters > 0 > income Statement > income Tax Expense
250
Quarters > 0 > income Statement > EBITDA
-2292248
Quarters > 0 > income Statement > operating Margin
-531.424673561821
Quarters > 0 > income Statement > total Other Income Expense Net
8739
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
4115779
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
674036
Quarters > 0 > balance Sheet > inventories
527004
Quarters > 0 > balance Sheet > total Current Assets
6309209
Quarters > 0 > balance Sheet > property Plant Equipment
227752
Quarters > 0 > balance Sheet > total Assets
6689344
Quarters > 0 > balance Sheet > payables
1391347
Quarters > 0 > balance Sheet > short Term Debt
8772
Quarters > 0 > balance Sheet > long Term Debt
144992
Quarters > 0 > balance Sheet > total Liabilities
2342386
Quarters > 0 > balance Sheet > equity
4430220
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-2315094
Quarters > 0 > cash Flow > depreciation
22830
Quarters > 0 > cash Flow > change In Working Capital
-159651
Quarters > 0 > cash Flow > cash From Operations
-2109072
Quarters > 0 > cash Flow > capital Expenditures
9998
Quarters > 0 > cash Flow > cash From Investing
-25487
Quarters > 0 > cash Flow > cash From Financing
4282178
Quarters > 0 > cash Flow > net Change In Cash
2148849
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.6304161688759912
Quarters > 0 > ratios > PB
0.506069285498237
Quarters > 0 > ratios > ROE
-52.300698385181775
Quarters > 0 > ratios > ROA
-34.63771634408396
Quarters > 0 > ratios > FCF
-2119070
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-4.842459586564961
Quarters > 0 > health Score
30
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
100932
Quarters > 1 > income Statement > cost Of Revenue
50051
Quarters > 1 > income Statement > gross Profit
50881
Quarters > 1 > income Statement > operating Expenses
1655709
Quarters > 1 > income Statement > operating Income
-1604828
Quarters > 1 > income Statement > interest Expense
1221
Quarters > 1 > income Statement > pretax Income
-1733430
Quarters > 1 > income Statement > net Income
-1733726
Quarters > 1 > income Statement > eps
-1.1770904975317251
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
1472891
Quarters > 1 > income Statement > income Tax Expense
1500
Quarters > 1 > income Statement > EBITDA
-1712531
Quarters > 1 > income Statement > operating Margin
-1590.009115047755
Quarters > 1 > income Statement > total Other Income Expense Net
-128602
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
1966930
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
295034
Quarters > 1 > balance Sheet > inventories
799421
Quarters > 1 > balance Sheet > total Current Assets
3844355
Quarters > 1 > balance Sheet > property Plant Equipment
193879
Quarters > 1 > balance Sheet > total Assets
4181937
Quarters > 1 > balance Sheet > payables
905813
Quarters > 1 > balance Sheet > short Term Debt
8772
Quarters > 1 > balance Sheet > long Term Debt
145477
Quarters > 1 > balance Sheet > total Liabilities
1836233
Quarters > 1 > balance Sheet > equity
2428254
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-1716484
Quarters > 1 > cash Flow > depreciation
19678
Quarters > 1 > cash Flow > change In Working Capital
46057
Quarters > 1 > cash Flow > cash From Operations
-1450128
Quarters > 1 > cash Flow > capital Expenditures
47322
Quarters > 1 > cash Flow > cash From Investing
-51684
Quarters > 1 > cash Flow > cash From Financing
0
Quarters > 1 > cash Flow > net Change In Cash
-1484570
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.1770904975317251
Quarters > 1 > ratios > PB
0.3700039246306194
Quarters > 1 > ratios > ROE
-71.39804979215518
Quarters > 1 > ratios > ROA
-41.4574872840026
Quarters > 1 > ratios > FCF
-1497450
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-14.836226370229461
Quarters > 1 > health Score
30
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
163552
Quarters > 2 > income Statement > cost Of Revenue
73272
Quarters > 2 > income Statement > gross Profit
90280
Quarters > 2 > income Statement > operating Expenses
2001155
Quarters > 2 > income Statement > operating Income
-1910875
Quarters > 2 > income Statement > interest Expense
1790
Quarters > 2 > income Statement > pretax Income
-1877238
Quarters > 2 > income Statement > net Income
-1876549
Quarters > 2 > income Statement > eps
-1.462099384321468
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
1283462
Quarters > 2 > income Statement > income Tax Expense
63
Quarters > 2 > income Statement > EBITDA
-1858651
Quarters > 2 > income Statement > operating Margin
-1168.359298571708
Quarters > 2 > income Statement > total Other Income Expense Net
33637
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
3451500
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
488243
Quarters > 2 > balance Sheet > inventories
773238
Quarters > 2 > balance Sheet > total Current Assets
5650231
Quarters > 2 > balance Sheet > property Plant Equipment
155792
Quarters > 2 > balance Sheet > total Assets
5977867
Quarters > 2 > balance Sheet > payables
1157979
Quarters > 2 > balance Sheet > short Term Debt
8772
Quarters > 2 > balance Sheet > long Term Debt
146502
Quarters > 2 > balance Sheet > total Liabilities
1948978
Quarters > 2 > balance Sheet > equity
4110235
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-1877301
Quarters > 2 > cash Flow > depreciation
16797
Quarters > 2 > cash Flow > change In Working Capital
81480
Quarters > 2 > cash Flow > cash From Operations
-1597366
Quarters > 2 > cash Flow > capital Expenditures
5482
Quarters > 2 > cash Flow > cash From Investing
1702518
Quarters > 2 > cash Flow > cash From Financing
1696899
Quarters > 2 > cash Flow > net Change In Cash
1792147
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1.462099384321468
Quarters > 2 > ratios > PB
0.1904786028049491
Quarters > 2 > ratios > ROE
-45.65551604713599
Quarters > 2 > ratios > ROA
-31.39161510284521
Quarters > 2 > ratios > FCF
-1602848
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-9.800234787712776
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
261440
Quarters > 3 > income Statement > cost Of Revenue
118077
Quarters > 3 > income Statement > gross Profit
143363
Quarters > 3 > income Statement > operating Expenses
2219193
Quarters > 3 > income Statement > operating Income
-2075829
Quarters > 3 > income Statement > interest Expense
1422
Quarters > 3 > income Statement > pretax Income
-2049424
Quarters > 3 > income Statement > net Income
-2048773
Quarters > 3 > income Statement > eps
-4.50693824216533
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
454582
Quarters > 3 > income Statement > income Tax Expense
-501
Quarters > 3 > income Statement > EBITDA
-2032050
Quarters > 3 > income Statement > operating Margin
-793.9982405140759
Quarters > 3 > income Statement > total Other Income Expense Net
26405
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
1659353
Quarters > 3 > balance Sheet > short Term Investments
1728472
Quarters > 3 > balance Sheet > receivables
486748
Quarters > 3 > balance Sheet > inventories
442764
Quarters > 3 > balance Sheet > total Current Assets
5386277
Quarters > 3 > balance Sheet > property Plant Equipment
149808
Quarters > 3 > balance Sheet > total Assets
5759345
Quarters > 3 > balance Sheet > payables
1007618
Quarters > 3 > balance Sheet > short Term Debt
8772
Quarters > 3 > balance Sheet > long Term Debt
147119
Quarters > 3 > balance Sheet > total Liabilities
1804339
Quarters > 3 > balance Sheet > equity
4035600
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-2048924
Quarters > 3 > cash Flow > depreciation
15947
Quarters > 3 > cash Flow > change In Working Capital
218929
Quarters > 3 > cash Flow > cash From Operations
-1638217
Quarters > 3 > cash Flow > capital Expenditures
2098
Quarters > 3 > cash Flow > cash From Investing
-2098
Quarters > 3 > cash Flow > cash From Financing
973
Quarters > 3 > cash Flow > net Change In Cash
-1641335
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-4.50693824216533
Quarters > 3 > ratios > PB
0.06871221627515116
Quarters > 3 > ratios > ROE
-50.767494300723556
Quarters > 3 > ratios > ROA
-35.57302089039639
Quarters > 3 > ratios > FCF
-1640315
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-6.274154681762546
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
607574
Annuals > 0 > income Statement > cost Of Revenue
384765
Annuals > 0 > income Statement > gross Profit
222809
Annuals > 0 > income Statement > operating Expenses
9937740
Annuals > 0 > income Statement > operating Income
-9714931
Annuals > 0 > income Statement > interest Expense
7912
Annuals > 0 > income Statement > pretax Income
-7955413
Annuals > 0 > income Statement > net Income
-7947107
Annuals > 0 > income Statement > eps
-17.48222982872177
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
454582
Annuals > 0 > income Statement > income Tax Expense
250
Annuals > 0 > income Statement > EBITDA
-7883756
Annuals > 0 > income Statement > operating Margin
-1598.97082495301
Annuals > 0 > income Statement > total Other Income Expense Net
1759518
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1659353
Annuals > 0 > balance Sheet > short Term Investments
1728472
Annuals > 0 > balance Sheet > receivables
486748
Annuals > 0 > balance Sheet > inventories
442764
Annuals > 0 > balance Sheet > total Current Assets
5386277
Annuals > 0 > balance Sheet > property Plant Equipment
149808
Annuals > 0 > balance Sheet > total Assets
5759345
Annuals > 0 > balance Sheet > payables
1007618
Annuals > 0 > balance Sheet > short Term Debt
8772
Annuals > 0 > balance Sheet > long Term Debt
147119
Annuals > 0 > balance Sheet > total Liabilities
1804339
Annuals > 0 > balance Sheet > equity
4035600
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-7955663
Annuals > 0 > cash Flow > depreciation
63745
Annuals > 0 > cash Flow > change In Working Capital
192724
Annuals > 0 > cash Flow > cash From Operations
-5648088
Annuals > 0 > cash Flow > capital Expenditures
181114
Annuals > 0 > cash Flow > cash From Investing
-1889114
Annuals > 0 > cash Flow > cash From Financing
7053571
Annuals > 0 > cash Flow > net Change In Cash
-483132
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-17.48222982872177
Annuals > 0 > ratios > PB
0.05802239771037764
Annuals > 0 > ratios > ROE
-196.92504212508672
Annuals > 0 > ratios > ROA
-137.9862987891852
Annuals > 0 > ratios > FCF
-5829202
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-9.594225559355733
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
253573
Annuals > 1 > income Statement > cost Of Revenue
474550
Annuals > 1 > income Statement > gross Profit
-220977
Annuals > 1 > income Statement > operating Expenses
4933606
Annuals > 1 > income Statement > operating Income
-5154583
Annuals > 1 > income Statement > interest Expense
2286637
Annuals > 1 > income Statement > pretax Income
-3813550
Annuals > 1 > income Statement > net Income
-3765702
Annuals > 1 > income Statement > eps
-0.9508676154211319
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
3960280
Annuals > 1 > income Statement > income Tax Expense
250
Annuals > 1 > income Statement > EBITDA
-1426545
Annuals > 1 > income Statement > operating Margin
-2032.7806982604613
Annuals > 1 > income Statement > total Other Income Expense Net
1341033
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
2142485
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
231332
Annuals > 1 > balance Sheet > inventories
466169
Annuals > 1 > balance Sheet > total Current Assets
7242588
Annuals > 1 > balance Sheet > property Plant Equipment
71278
Annuals > 1 > balance Sheet > total Assets
7783771
Annuals > 1 > balance Sheet > payables
506206
Annuals > 1 > balance Sheet > short Term Debt
22422
Annuals > 1 > balance Sheet > long Term Debt
150251
Annuals > 1 > balance Sheet > total Liabilities
2985675
Annuals > 1 > balance Sheet > equity
4870134
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-3765702
Annuals > 1 > cash Flow > depreciation
100372
Annuals > 1 > cash Flow > change In Working Capital
405364
Annuals > 1 > cash Flow > cash From Operations
-4542910
Annuals > 1 > cash Flow > capital Expenditures
115888
Annuals > 1 > cash Flow > cash From Investing
-115888
Annuals > 1 > cash Flow > cash From Financing
6474565
Annuals > 1 > cash Flow > net Change In Cash
1877620
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.9508676154211319
Annuals > 1 > ratios > PB
0.41886737161646886
Annuals > 1 > ratios > ROE
-77.3223488306482
Annuals > 1 > ratios > ROA
-48.37888987227399
Annuals > 1 > ratios > FCF
-4658798
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-18.372610648610063
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
223208
Annuals > 2 > income Statement > cost Of Revenue
432370
Annuals > 2 > income Statement > gross Profit
-209162
Annuals > 2 > income Statement > operating Expenses
1541283
Annuals > 2 > income Statement > operating Income
-1750445
Annuals > 2 > income Statement > interest Expense
3989359
Annuals > 2 > income Statement > pretax Income
-6177284
Annuals > 2 > income Statement > net Income
-6181720
Annuals > 2 > income Statement > eps
-1.069170065410505
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
5781793
Annuals > 2 > income Statement > income Tax Expense
500
Annuals > 2 > income Statement > EBITDA
-2109139
Annuals > 2 > income Statement > operating Margin
-784.2214436758538
Annuals > 2 > income Statement > total Other Income Expense Net
-4426839
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
264865
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
45965
Annuals > 2 > balance Sheet > inventories
518578
Annuals > 2 > balance Sheet > total Current Assets
1099004
Annuals > 2 > balance Sheet > property Plant Equipment
33947
Annuals > 2 > balance Sheet > total Assets
1297206
Annuals > 2 > balance Sheet > payables
758668
Annuals > 2 > balance Sheet > short Term Debt
21148246
Annuals > 2 > balance Sheet > long Term Debt
1270055
Annuals > 2 > balance Sheet > total Liabilities
25446266
Annuals > 2 > balance Sheet > equity
-23576740
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-6177784
Annuals > 2 > cash Flow > depreciation
78786
Annuals > 2 > cash Flow > change In Working Capital
3306493
Annuals > 2 > cash Flow > cash From Operations
-1009980
Annuals > 2 > cash Flow > capital Expenditures
60133
Annuals > 2 > cash Flow > cash From Investing
-60133
Annuals > 2 > cash Flow > cash From Financing
1221706
Annuals > 2 > cash Flow > net Change In Cash
149466
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-1.069170065410505
Annuals > 2 > ratios > PB
-0.1263194815865128
Annuals > 2 > ratios > ROE
26.219570644626867
Annuals > 2 > ratios > ROA
-476.5411199146473
Annuals > 2 > ratios > FCF
-1070113
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.794241245833483
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1160340
Annuals > 3 > income Statement > cost Of Revenue
850742
Annuals > 3 > income Statement > gross Profit
309598
Annuals > 3 > income Statement > operating Expenses
1433700
Annuals > 3 > income Statement > operating Income
-1124102
Annuals > 3 > income Statement > interest Expense
3172712
Annuals > 3 > income Statement > pretax Income
-4259299
Annuals > 3 > income Statement > net Income
-4251745
Annuals > 3 > income Statement > eps
-0.7353679040394563
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
5781793
Annuals > 3 > income Statement > income Tax Expense
1000
Annuals > 3 > income Statement > EBITDA
-1014802
Annuals > 3 > income Statement > operating Margin
-96.87694985952393
Annuals > 3 > income Statement > total Other Income Expense Net
-3135197
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
115399
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
146362
Annuals > 3 > balance Sheet > inventories
689042
Annuals > 3 > balance Sheet > total Current Assets
1176672
Annuals > 3 > balance Sheet > property Plant Equipment
107615
Annuals > 3 > balance Sheet > total Assets
1393527
Annuals > 3 > balance Sheet > payables
588678
Annuals > 3 > balance Sheet > short Term Debt
46795
Annuals > 3 > balance Sheet > long Term Debt
18744795
Annuals > 3 > balance Sheet > total Liabilities
19548011
Annuals > 3 > balance Sheet > equity
-17578228
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-4260299
Annuals > 3 > cash Flow > depreciation
71785
Annuals > 3 > cash Flow > change In Working Capital
2896491
Annuals > 3 > cash Flow > cash From Operations
-649106
Annuals > 3 > cash Flow > capital Expenditures
35392
Annuals > 3 > cash Flow > cash From Investing
-35392
Annuals > 3 > cash Flow > cash From Financing
611226
Annuals > 3 > cash Flow > net Change In Cash
-76303
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.7353679040394563
Annuals > 3 > ratios > PB
-0.16942558569043478
Annuals > 3 > ratios > ROE
24.187563160518796
Annuals > 3 > ratios > ROA
-305.106754300419
Annuals > 3 > ratios > FCF
-684498
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-0.5899115776410363
Annuals > 3 > health Score
31
Valuation > metrics > PE
-0.6304161688759912
Valuation > metrics > PB
0.506069285498237
Valuation > final Score
70
Valuation > verdict
49.4% Undervalued
Profitability > metrics > ROE
-52.300698385181775
Profitability > metrics > ROA
-36.72466706999245
Profitability > metrics > Net Margin
-5.2948478297631185
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.5287290473159346
Risk > metrics > Interest Coverage
-1361.5485948477751
Risk > final Score
-5398
Risk > verdict
High
Liquidity > metrics > Current Ratio
4.506194830582258
Liquidity > metrics > Quick Ratio
4.129795395962772
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-5209
Prev Risks > 1
-4210
Prev Risks > 2
-5779
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:39:41.826Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-28
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.67
Earnings History > 0 > eps Estimate
-0.08
Earnings History > 0 > eps Difference
-0.59
Earnings History > 0 > surprise Percent
-737.5
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-13
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-1.26
Earnings History > 1 > eps Estimate
-0.1
Earnings History > 1 > eps Difference
-1.16
Earnings History > 1 > surprise Percent
-1160
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-15
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.55
Earnings History > 2 > eps Estimate
-0.11
Earnings History > 2 > eps Difference
-1.44
Earnings History > 2 > surprise Percent
-1309.0909
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-26
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-2.16
Earnings History > 3 > eps Estimate
-0.18
Earnings History > 3 > eps Difference
-1.98
Earnings History > 3 > surprise Percent
-1100
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-14
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.93
Earnings History > 4 > eps Estimate
-0.22
Earnings History > 4 > eps Difference
-0.71
Earnings History > 4 > surprise Percent
-322.7273
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-28
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-4.24
Earnings History > 5 > eps Estimate
-0.21
Earnings History > 5 > eps Difference
-4.03
Earnings History > 5 > surprise Percent
-1919.0476
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-15
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
0.03
Earnings History > 6 > eps Estimate
-0.15
Earnings History > 6 > eps Difference
0.18
Earnings History > 6 > surprise Percent
120
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-02-28
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.345
Earnings History > 7 > eps Estimate
-0.14
Earnings History > 7 > eps Difference
-0.205
Earnings History > 7 > surprise Percent
-146.4286
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-11-20
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
0.77
Earnings History > 8 > eps Estimate
0.95
Earnings History > 8 > eps Difference
-0.18
Earnings History > 8 > surprise Percent
-18.9474
Earnings History > 9 > period
2023-06-30
Earnings History > 9 > report Date
2023-08-30
Earnings History > 9 > date
2023-06-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-1.1
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-1.1
Earnings History > 9 > surprise Percent
-
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A60 Degrees Pharmaceuticals (SXTP) to Implement 1-for-4 Reverse Stock Split Effective January 20, 2026 Intellectia AI
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$4.4
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Neutral
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of 60 Degrees Pharmaceuticals, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.67
EPS Estimate
-0.08
EPS Difference
-0.59
Surprise Percent
-737.5%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.